查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918336

醫藥級乳糖市場－2026-2031年預測

Pharmaceutical Grade Lactose Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計藥用級乳糖市場將從 2025 年的 20.06 億美元成長到 2031 年的 27.52 億美元，複合年成長率為 5.41%。

全球藥用級乳糖市場是一個主要源自於乳酪生產的專業細分市場，其產品符合嚴格的醫藥應用品質標準。這種高純度乳糖主要用作賦形劑，惰性物質，可作為活性藥物成分 (API) 的載體，改善製劑的流動性、可壓性、穩定性和口感。其主要應用包括片劑和膠囊劑的生產、乾粉吸入劑 (DPI)、口服液，以及作為注射劑和吸入劑的稀釋劑或填充劑。此外，藥用級乳糖也為嬰幼兒奶粉提供必需的碳水化合物和能源來源，支持嬰幼兒的早期營養和發育。人們對乳糖在兒童營養和藥物療效方面的益處的認知不斷提高，加上全球醫療保健支出的成長，正在推動市場擴張。人口老化和慢性病發病率的上升進一步刺激了市場需求，乳糖有助於生產常用的口服固體製劑常用於治療癌症、糖尿病、心血管疾病和其他疾病。

關鍵市場促進因素反映了醫療保健結構的趨勢：對製藥業的投資不斷成長，尤其是在印度和巴西等新興經濟體，這提高了學名藥和慢性病新治療方法的生產能力，直接推動了對輔料的需求。

慢性疾病發生率不斷上升，尤其是預計未來 20 年新增癌症病例將增加 70%，這推動了抗癌藥物的需求，而乳糖是這些藥物的關鍵稀釋劑和填充劑。

藥用級乳糖用途廣泛，已成為各種配方中多種應用的首選輔料，包括控制釋放、掩味、提高原料藥穩定性以及提高溶解度和生物利用度。

隨著全球人口老化加劇，治療與老齡化相關的慢性疾病的藥物需求不斷成長，而乳糖是製造常見藥片和膠囊的重要成分。

從細分市場來看，α-乳糖一水合物類別預計將主導市場並實現顯著成長，因為與其他乳糖變體相比，它具有更優異的延長保存期限特性，因此被廣泛用作固態劑型和乾粉吸入劑 (DPI) 中的填充劑、稀釋劑和載體。

按地區分類，預計北美將繼續保持顯著的市場佔有率和健康的複合年成長率。該地區的主導地位歸功於主要生產商和供應商的集中，以及全球製藥領導者美國製藥業的強勁成長。乳糖作為片劑、膠囊、口服液和吸入粉劑輔料的日益普及也支撐了市場需求。此外，人們普遍認為乳糖配方奶粉有益於消化器官系統，並能減少嬰兒胃腸道疾病，加上家長和專業人士對此意識提升，也推動了奶粉的普及。

重點產品具有特殊的性能特性。

Armor Protein 的 ArmorPharma™ 乳糖一水合物 200M 是一種精細研磨的 α-乳糖一水合物粉末，針對片劑生產中的濕法和乾法製粒進行了最佳化，具有優異的混合和壓片性能。

Charotar Casein 公司生產的「乳糖製藥」經過嚴格的品管，精心加工，達到低水分（5.10%）和低酸度（0.20），確保高純度、透明度和有效性。

BASF的Rudypress®是一種共加工顆粒，由一水乳糖（93%）、Kollidon® 30（3.5%）和Kollidon® CL（3.5%）製成。這種白色、流動性好、無味的物質簡化了片劑生產過程，並能生產出硬度高、不易碎的片劑，這些片劑能夠快速崩壞並釋放活性成分。

藥用級乳糖市場受益於多種因素的共同推動，包括慢性病發病率上升、人口老化、乳糖作為輔料的多功能性以及製藥業的投資。北美的製造生態系統和製劑應用鞏固了該地區的地位，而α-乳糖一水合物的功能優勢則使其在該領域佔據主導地位。隨著全球醫療費用支出不斷成長，以及人們對乳糖在藥物輸送和嬰幼兒營養中的作用認知不斷提高，該領域為專注於純度合規、客製化和應用創新的供應商提供了持續的機會。業內相關人員應密切關注監管政策的變化和新興的治療方法，以最佳化其在這個蓬勃發展的輔料領域的市場定位。

本報告的主要優勢：

  • 深入分析：獲得主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要企業的策略舉措，並了解透過正確的策略進入市場的可能性。
  • 市場促進因素與未來趨勢：探討影響市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在快速變化的環境中製定策略決策，發展新的商業機會和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業使用我們的報告的目的是什麼？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊）及主要發展動態。

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 依產品類型分類的藥用級乳糖市場

  • 介紹
  • BETA-乳糖
  • α-乳糖一水合物
  • 無定形乳糖
  • 噴霧乾燥乳糖

6. 依應用分類的藥用級乳糖市場

  • 介紹
  • 藥片
  • 膠囊
  • 乾粉吸入器（DPI）
  • 小袋
  • 注射劑（填充劑）
  • 口服懸浮液

7. 以最終用戶分類的醫藥級乳糖市場

  • 介紹
  • 製藥公司
  • 契約製造組織（CMO）
  • 合約研發生產組織（CDMO）
  • 營養補充品製造商
  • 研究與開發實驗室

8. 按地區分類的藥用級乳糖市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Armor Proteines（Savencia Group）
  • BASF Corporation
  • Charotar Casein Company
  • Fengchen Group Co., Ltd.
  • Alpavit
  • Kavya Pharma
  • Lactose（India）Limited
  • MEGGLE GmbH & Co. KG
  • FrieslandCampina
  • Surfachem Group Ltd.（2M Holdings）.

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061616350

Pharmaceutical Grade Lactose Market is projected to increase at a 5.41% CAGR, growing from USD 2.006 billion in 2025 to USD 2.752 billion in 2031.

The global pharmaceutical-grade lactose market represents a specialized segment derived primarily from cheese production byproducts, adhering to rigorous quality standards for pharmaceutical applications. This high-purity lactose functions predominantly as an excipient-an inert substance serving as a vehicle for active pharmaceutical ingredients (APIs)-enhancing flowability, compressibility, stability, and taste in formulations. Key uses include tablet and capsule production, dry powder inhalers (DPIs), oral solutions, and as a diluent or filler in injectable and inhalable drugs. Additionally, pharmaceutical-grade lactose provides essential carbohydrates and energy in infant formulas, supporting early childhood nutrition and development. Rising awareness of its benefits in pediatric nutrition and pharmaceutical efficacy, coupled with escalating global healthcare expenditures, is propelling market expansion. The aging population and increasing prevalence of chronic diseases further amplify demand, as lactose facilitates oral solid dosage forms commonly prescribed for conditions like cancer, diabetes, and cardiovascular disorders.

Primary market drivers underscore structural healthcare trends. Growing investments in pharmaceutical manufacturing, particularly in emerging economies like India and Brazil, bolster production capacities for generics and novel therapies targeting chronic illnesses, directly elevating excipient requirements.

Rising chronic disease incidence, notably cancer-projected for a 70% increase in new cases over the next two decades-heightens demand for anticancer medications where lactose serves as a critical diluent and filler.

The versatility of pharmaceutical-grade lactose across applications-drug release modification, flavor masking, API stability enhancement, and improved solubility/bioavailability-positions it as a preferred excipient in diverse formulations.

Demographic shifts toward an older global population drive medication needs for age-related chronic conditions, with lactose integral to prevalent tablet and capsule formats.

From a segmentation perspective, the a-lactose monohydrate category is anticipated to dominate and exhibit substantial growth. Its widespread adoption as a filler, diluent, and carrier in solid dosage forms and DPIs stems from superior shelf-life extension compared to other lactose variants.

Geographically, North America is projected to maintain a significant market share and healthy CAGR. The region's leadership arises from a concentration of major producers and suppliers, alongside robust pharmaceutical industry growth in the United States-a leading global market for drug products. Increasing incorporation of lactose as an excipient in tablets, capsules, oral solutions, and inhalation powders supports demand. Furthermore, recognition of lactose-based infant formulas' digestive benefits and reduced gastrointestinal issues in infants is fostering formula uptake amid heightened parental and professional awareness.

Leading product offerings highlight specialized performance characteristics.

ARMOR PROTEINS' ARMOR PHARMA(TM) lactose monohydrate 200M is a finely milled a-lactose monohydrate powder optimized for wet and dry granulation in tablet production, delivering excellent mixing and compaction properties.

Charotar Casein Company's Lactose pharma undergoes meticulous processing to achieve low moisture (5.10%) and acidity (0.20), ensuring high purity, clarity, and efficacy under stringent quality controls.

BASF Corporation's Ludipress(R) is a co-processed granulate comprising lactose monohydrate (93%), Kollidon(R) 30 (3.5%), and Kollidon(R) CL (3.5%). This white, free-flowing, tasteless material simplifies tableting, yielding hard, low-friability tablets with rapid disintegration and API release.

The pharmaceutical-grade lactose market is underpinned by converging factors: chronic disease proliferation, geriatric demographics, excipient versatility, and pharmaceutical sector investments. North America's manufacturing ecosystem and formulation adoption reinforce its prominence, while a-lactose monohydrate's functional superiority drives segmental leadership. As global healthcare spending rises and awareness of lactose's role in drug delivery and infant nutrition grows, the sector presents sustained opportunities for suppliers focusing on purity compliance, customization, and application-specific innovations. Industry participants should monitor regulatory alignments and emerging therapies to optimize positioning in this resilient excipient category.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Pharmaceutical Grade Lactose Market Segmentation

  • By Product Type
  • B-lactose
  • a-Lactose monohydrate
  • Amorphous Lactose
  • Spray Dried Lactose
  • By Application
  • Tablets
  • Capsules
  • Dry Powder Inhalers (DPI)
  • Sachets
  • Parenteral Formulations (Bulking Agent)
  • Oral Suspensions
  • By End-User
  • Pharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Nutraceutical Manufacturers
  • Research & Development Laboratories
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PHARMACEUTICAL GRADE LACTOSE MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. B-lactose
  • 5.3. a-Lactose monohydrate
  • 5.4. Amorphous Lactose
  • 5.5. Spray Dried Lactose

6. PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Tablets
  • 6.3. Capsules
  • 6.4. Dry Powder Inhalers (DPI)
  • 6.5. Sachets
  • 6.6. Parenteral Formulations (Bulking Agent)
  • 6.7. Oral Suspensions

7. PHARMACEUTICAL GRADE LACTOSE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical Companies
  • 7.3. Contract Manufacturing Organizations (CMOs)
  • 7.4. Contract Development & Manufacturing Organizations (CDMOs)
  • 7.5. Nutraceutical Manufacturers
  • 7.6. Research & Development Laboratories

8. PHARMACEUTICAL GRADE LACTOSE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Thailand
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Armor Proteines (Savencia Group)
  • 10.2. BASF Corporation
  • 10.3. Charotar Casein Company
  • 10.4. Fengchen Group Co., Ltd.
  • 10.5. Alpavit
  • 10.6. Kavya Pharma
  • 10.7. Lactose (India) Limited
  • 10.8. MEGGLE GmbH & Co. KG
  • 10.9. FrieslandCampina
  • 10.10. Surfachem Group Ltd. (2M Holdings).

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations